Michael Chen, MD
Internal Medicine · Stayton, ORNPI 1619926011
Payments from drug & device makers
Across 187 payments — averaging $6605.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Janssen Research & Development, LLC$589K
- Eli Lilly$552K
- Novo Nordisk AS$83K
- Sanofi US Services Inc.$11K
- Amgen$146
- Pfizer$64
- plus $328 from 12 others
Across 6 payments — averaging $2432.07 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$15K
What the payments were for
- Speaking & faculty fees$8015%
- Food & beverage$44282%
- Education$163%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Janssen Research & Development, LLC | 20 | $588,735 |
| Eli Lilly | 22 | $551,664 |
| Novo Nordisk AS | 115 | $83,089 |
| Sanofi US Services Inc. | 6 | $11,272 |
| Amgen | 6 | $146 |
| Pfizer | 3 | $64 |
| BD | 2 | $55 |
| Novartis | 2 | $39 |
| GSK | 2 | $39 |
| Teleflex LLC | 1 | $32 |
| Abiomed | 1 | $32 |
| E.r. Squibb & Sons, L.L.C. | 1 | $30 |
| Sanofi-aventis U.S. LLC | 1 | $25 |
| Abbott | 1 | $22 |
| AstraZeneca | 1 | $16 |
| Philips North America LLC | 1 | $14 |
| Corcept Therapeutics | 1 | $13 |
| Circassia Inc. | 1 | $12 |
How this compares
$1,235,298 in reported general payments places this provider in the 95th percentile of 1,363 internal medicine providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 172 | $238,777 |
| JardianceEmpagliflozin | 157 | $206,456 |
| EliquisApixaban | 124 | $148,010 |
| TrulicityDulaglutide | 78 | $113,510 |
| MounjaroTirzepatide | 68 | $99,493 |
| FarxigaDapagliflozin Propanediol | 37 | $44,477 |
| Bydureon BciseExenatide Microspheres | 31 | $30,065 |
| EntrestoSacubitril/Valsartan | 14 | $25,887 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 26 | $20,014 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 25 | $17,006 |
| Arnuity ElliptaFluticasone Furoate | 31 | $9,116 |
| Incruse ElliptaUmeclidinium Bromide | 23 | $7,920 |
| Rosuvastatin Calcium | 505 | $7,658 |
| Breo ElliptaFluticasone/Vilanterol | 17 | $6,444 |
| SynthroidLevothyroxine Sodium | 65 | $6,384 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $64 | $148,010124 claims |
| AstraZenecaFarxiga | $16 | $44,47737 claims |
| GSKTrelegy Ellipta, Arnuity Ellipta, Incruse Ellipta, Breo Ellipta | $39 | $43,49397 claims |
| NovartisEntresto | $39 | $25,88714 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,363 internal medicine providers in Oregon.
Other internal medicine in Stayton
- Stephen SpurgeonPortland$8.6M
- Drissana TranSalem$4.8M
- James BergtholdPortland$4.7M
- Stephen FortmannPortland$3.3M
- Maryann ConradPortland$2.7M
- Brian CurtisCorvallis$2.4M
- Jennifer SaultzPortland$1.9M
- Elizabeth LilesHillsboro$1.9M
- Marc UemuraEugene$1.6M
- Robin McKelveyCorvallis$806K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.